SSc-ILD Patients Treated with Nintedanib at high risk of weight loss and malnutrition
In a recent study published in the Arthritis Care & Research found the impact of nintedanib treatment on adverse events (AEs) and the risk of malnutrition in patients with systemic sclerosis–associated interstitial lung disease (SSc–ILD) based on their baseline body mass index (BMI).
The study investigated patients with SSc–ILD randomized to receive either nintedanib or a placebo over a span of 52 weeks, scrutinized AEs in two subgroups: those with a baseline BMI ≤20 kg/m² and those with a baseline BMI >20 kg/m². Additionally, the risk of malnutrition was assessed using a modified version of the Malnutrition Universal Screening Tool (MUST).
Remarkably, the analysis unveiled that the AE profile of nintedanib was comparable in both subgroups, regardless of baseline BMI. In the subgroup with a baseline BMI ≤20 kg/m², AEs resulted in treatment discontinuation for 16.7% of the nintedanib group, as opposed to 13.5% in the placebo group. In the subgroup with a baseline BMI >20 kg/m², these figures stood at 15.9% for nintedanib and 8.0% for placebo.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.